

Supplementary Table 3. Baseline characteristics of cases stratified by living type

Variable	Total			Men			Women		
	Living alone	Cohabiting	P value	Living alone	Cohabiting	P value	Living alone	Cohabiting	P value
Number	527 (19.4)	2,184 (80.6)		226 (13.6)	1,430 (86.4)		301 (28.5)	754 (71.5)	
Age (yr)	71.1±12.5	67.7±12.4	<0.01	64.0±13.3	65.9±12.0	0.04	76.6±8.4	71.2±12.3	<0.1
Risk factors									
Hypertension	352 (66.8)	1,339 (61.3)	0.02	140 (61.9)	841 (58.8)	0.37	212 (70.4)	498 (66.0)	0.17
Diabetes mellitus	153 (29.0)	667 (30.5)	0.50	56 (24.8)	452 (31.6)	0.04	97 (32.2)	215 (28.5)	0.23
Smoking status	151 (28.7)	624 (28.6)	<0.01	130 (57.5)	577 (40.3)	<0.01	21 (7.0)	47 (6.2)	0.27
Previous history of coronary artery disease	75 (14.2)	288 (13.2)	0.53	31 (13.7)	209 (14.6)	0.72	44 (14.6)	79 (10.5)	0.06
Previous history of cerebrovascular disease	96 (18.2)	437 (20.0)	0.35	40 (17.7)	285 (19.9)	0.43	56 (18.6)	152 (20.2)	0.57
Previous history of atrial fibrillation	141 (26.8)	506 (23.2)	0.08	38 (16.8)	293 (20.5)	0.20	103 (34.2)	213 (28.2)	0.06
History of statin use	81 (15.4)	394 (18.0)	0.15	29 (12.8)	255 (17.8)	0.06	52 (17.3)	139 (18.4)	0.66
Time delay from onset to hospital arrival, median (IQR)	617–1,604	530.5–1,212.25	0.05	653–1,883.5	531–1,269.75	0.08	600–1,433	527–1,107.5	0.22
Time delay from onset to hospital arrival, range	12–11,213	7–11,408		19–11,213	7–11,408		12–11,127	13–11,230	
Arrival at the hospital 4.5 hr within onset	159 (30.2)	751 (34.4)	0.07	70 (31.0)	500 (35.0)	0.24	89 (29.6)	251 (33.3)	0.24
Use of intravenous tissue plasminogen activator	79 (18.2)	454 (25.3)	<0.01	34 (18.4)	303 (26.0)	0.03	45 (18.1)	151 (24.0)	0.06
Door-to-needle time, median (IQR)	32–17	29–16	0.14	32–17	30–16	0.93	32–15	29–15.5	0.16
Door-to-needle time, range	10–290	10–171		10–55	10–124		11–290	11–171	
Intraarterial thrombectomy	39 (7.4)	198 (9.1)	0.22	14 (6.2)	126 (8.8)	0.19	25 (8.3)	72 (9.5)	0.53
Door-to-puncture time, median (IQR)	109–39	102.5–39.5	0.89	106.5–28.5	101.5–42.25	0.722	124–46	103.5–40.5	
Door-to-puncture time, range	52–181	16–1,049		72–150	16–445		52–181	35–1,049	
NIHSS score at admission	7.4±6.4	6.1±6.2	<0.01	6.7±6.1	5.7±5.9	0.02	7.9±6.6	6.8±6.7	0.02
Stroke subtype									
Large artery atherosclerosis	192 (36.7)	768 (35.5)	0.14	91 (40.8)	538 (38.0)	0.29	101 (33.7)	230 (30.8)	0.05
Cardioembolism	132 (25.2)	511 (23.6)		33 (14.8)	289 (20.4)		99 (33.0)	222 (29.7)	
Small-vessel occlusion	83 (15.9)	405 (18.7)		40 (17.9)	266 (18.8)		43 (14.3)	139 (18.6)	
Stroke of other determined etiologies	6 (1.1)	57 (2.6)		6 (2.7)	42 (3.0)		0	15 (2.0)	
Stroke of undetermined etiology	110 (21.0)	423 (19.5)		53 (23.8)	282 (19.9)		57 (19.0)	141 (18.9)	
mRS score poor functional outcome (3–6) at 90 days	271 (51.5)	819 (37.6)	<0.01	96 (42.5)	498 (34.9)	0.03	175 (58.3)	321 (42.9)	<0.01
mRS score poor functional outcome (3–6) at 1 year	205 (50.1)	621 (37.2)	<0.01	66 (38.8)	385 (34.9)	0.32	139 (58.2)	236 (41.5)	<0.01

Values are presented as mean±SD or number (%).

IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale.